News
AUTL
1.710
+6.88%
0.110
Autolus Therapeutics Q1 2026 Earnings Preview
Seeking Alpha · 10h ago
Weekly Report: what happened at AUTL last week (0504-0508)?
Weekly Report · 2d ago
Weekly Report: what happened at AUTL last week (0427-0501)?
Weekly Report · 05/04 09:46
Analyst Maintains Buy on Autolus, Reiterates $9 Price Target on Restructuring Savings and Clinical Catalysts
TipRanks · 04/30 10:27
Autolus Therapeutics Announces Workforce Reduction and Cost Restructuring
TipRanks · 04/29 22:57
Autolus Therapeutics to reduce workforce by approximately 13%
TipRanks · 04/29 22:04
Autolus Therapeutics Plans To Cut Workforce By ~13% As Part Of Initiative To Enhance Operational Efficiency, Lower Operating Expenses
Benzinga · 04/29 20:24
Autolus to cut about 13% of workforce in cost reduction initiative
Seeking Alpha · 04/29 20:20
Weekly Report: what happened at AUTL last week (0420-0424)?
Weekly Report · 04/27 09:47
Weekly Report: what happened at AUTL last week (0413-0417)?
Weekly Report · 04/20 09:45
Autolus Therapeutics: Strategic Positioning and Leadership Drive Confident Buy Rating
TipRanks · 04/14 11:15
Asgard Therapeutics names Wolfram Brugger as chief medical officer to lead clinical transition
Seeking Alpha · 04/14 10:07
Autolus Therapeutics files to sell 54.58M American Depositary Shares for holders
TipRanks · 04/13 10:06
Autolus Therapeutics files $150M mixed securities shelf
TipRanks · 04/13 10:06
Weekly Report: what happened at AUTL last week (0406-0410)?
Weekly Report · 04/13 09:47
Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham
Dow Jones · 04/09 11:23
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
Benzinga · 04/09 11:14
Autolus Therapeutics (AUTL) Receives a Buy from Needham
TipRanks · 04/09 10:58
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Assertio Therapeutics (ASRT) and Alibaba Health Information Technology (OtherALBHF)
TipRanks · 04/09 10:20
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Corcept Therapeutics (CORT)
TipRanks · 04/09 09:00
More
Webull provides a variety of real-time AUTL stock news. You can receive the latest news about AUTOLUS THERAPEUTICS PLC through multiple platforms. This information may help you make smarter investment decisions.
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.